MSD
@MSDInvents
Followers
24K
Following
512
Media
2K
Statuses
2K
We aspire to be the premier research-intensive biopharmaceutical company.
Global
Joined October 2016
We’re excited to share new data from our neuroscience pipeline at CTAD 2025, including results for two #AlzheimersDisease candidates. The U.S. FDA has granted Fast Track Designation to one of our candidates for the treatment of Alzheimer's. Learn more: https://t.co/9dOP8SpofG
0
1
4
Today, we announced an agreement to acquire Cidara Therapeutics, Inc., diversifying our respiratory portfolio to include an investigational long-acting strain-agnostic antiviral agent. https://t.co/a706symZNM
1
2
10
Today, we announced a strategic funding agreement with Blackstone, positioning our company to advance development of an investigational antibody-drug conjugate targeting TROP2 while we continue to advance our broad and expansive pipeline. Read more: https://t.co/WnEnjf2Rj9
2
0
8
Our Q3 2025 #earnings results are live. Check out our full financial summary and key highlights: https://t.co/QCZhqwNucd
1
0
1
We are pleased to announce that we’ve completed our acquisition of @VeronaPharma, bringing talented new colleagues into our company and strengthening our cardio‑pulmonary footprint. Learn more: https://t.co/PckakWjStX
1
0
4
Our Q2 2025 #earnings results are live. Check out our full financial summary and key highlights: https://t.co/15zrWg6x9D
0
1
5
Today we announced an agreement to acquire Verona Pharma. Through this acquisition, we will add a novel, important maintenance treatment for chronic obstructive pulmonary disease (#COPD) to strengthen & complement our diversified cardio-pulmonary portfolio https://t.co/q20i6I4xLf
0
2
5
Today, we announced the initiation of our Phase 3 clinical study in #dengue. Learn more: https://t.co/iFdyTZ7fEl
2
5
14
1
0
3
Our Q1 2025 #earnings results are live. Check out our full financial summary and key highlights: https://t.co/IhpGnkjJBj
0
1
2
Today, we announced an exclusive license to develop, manufacture and commercialize an investigational oral small molecule Lipoprotein(a), or Lp(a), inhibitor from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Learn more: https://t.co/R8ctBJZj3p
1
1
5
#ByTheNumbers: Check out highlights from our Q4 and full-year 2024 #earnings report: https://t.co/vkQJMm0A38
0
0
2
Our Q4 and full-year 2024 #earnings results are live. Check out our full financial summary and key highlights: https://t.co/vkQJMm0A38
0
0
2
Today we announced an exclusive global license to develop, manufacture and commercialize an investigational preclinical oral small molecule GLP-1 receptor agonist from Hansoh Pharma. Learn more: https://t.co/ITgZPObXBo
0
1
4
Today we announced an exclusive global license to develop, manufacture and commercialize a novel investigational bispecific antibody from LaNova Medicines Ltd. Learn more: https://t.co/dXSRTV8NEB
0
2
4